Trial · NCT00979654
Results by group17
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 17 of 17
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs) | Sifalimumab (MEDI-545) 500 or 600 Milligram (mg) | TEAEs | 101 | participants | |
| Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs) | Sifalimumab (MEDI-545) 500 or 600 Milligram (mg) | TESAEs | 27 | participants | |
| Maximum Observed Serum Concentration (Cmax) for Sifalimumab | Sifalimumab (MEDI-545) 500 or 600 Milligram (mg) | 225.569 | Standard Deviation 78.842 | microgram per milliliter (mcg/mL) | |
| Time to Reach Maximum Observed Plasma Concentration (Tmax) of Sifalimumab | Sifalimumab (MEDI-545) 500 or 600 Milligram (mg) | 0.049 | Full Range 0.04 to 0.13 | days | |
| Time to Last Quantifiable Plasma Concentration (Tlast) of Sifalimumab | Sifalimumab (MEDI-545) 500 or 600 Milligram (mg) | 14.413 | Standard Deviation 1.693 | days | |
| Minimum Observed Serum Concentration (Ctrough) of Sifalimumab | Sifalimumab (MEDI-545) 500 or 600 Milligram (mg) | 65.009 | Standard Deviation 30.516 | mcg/mL | |
| Area Under the Serum Concentration-time Curve Over the Dosing Interval (AUCtau) of Sifalimumab | Sifalimumab (MEDI-545) 500 or 600 Milligram (mg) | 2084.180 | Standard Deviation 665.882 | microgram.day per milliliter(mcg*day/mL) | |
| Minimum Observed Serum Concentration at Steady State (Ctrough,ss) of Sifalimumab | Sifalimumab (MEDI-545) 500 or 600 Milligram (mg) | 78.731 | Standard Deviation 53.942 | mcg/mL | |
| Accumulation Index for Minimum Observed Serum Concentration (Ctrough) of Sifalimumab | Sifalimumab (MEDI-545) 500 or 600 Milligram (mg) | 1.217 | Standard Deviation 0.808 | ratio | |
| Number of Participants With Positive Anti-Drug Antibody | Sifalimumab (MEDI-545) 500 or 600 Milligram (mg) | Day 1 | 5 | Participants | |
| Number of Participants With Positive Anti-Drug Antibody | Sifalimumab (MEDI-545) 500 or 600 Milligram (mg) | Week 12 | 0 | Participants | |
| Number of Participants With Positive Anti-Drug Antibody | Sifalimumab (MEDI-545) 500 or 600 Milligram (mg) | Week 24 | 0 | Participants | |
| Number of Participants With Positive Anti-Drug Antibody | Sifalimumab (MEDI-545) 500 or 600 Milligram (mg) | Week 52 | 1 | Participants | |
| Number of Participants With Positive Anti-Drug Antibody | Sifalimumab (MEDI-545) 500 or 600 Milligram (mg) | Week 104 | 4 | Participants | |
| Number of Participants With Positive Anti-Drug Antibody | Sifalimumab (MEDI-545) 500 or 600 Milligram (mg) | Week 156 | 1 | Participants | |
| Number of Participants With Positive Anti-Drug Antibody | Sifalimumab (MEDI-545) 500 or 600 Milligram (mg) | Week 168 | 4 | Participants | |
| Number of Participants With Positive Anti-Drug Antibody | Sifalimumab (MEDI-545) 500 or 600 Milligram (mg) | Any Day Post Baseline | 9 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00979654/results